Plus, news about Auron Therapeutics, Akribion Therapeutics, Enveric Biosciences and Valerio Therapeutics:
Turnstone Biologics to discontinue TIL studies, “review strategic alternatives”: The company announced it will discontinue studies of TIDAL-01, its ...
↧